School of Medicine
Showing 181-200 of 483 Results
-
Maya M. Kasowski
Assistant Professor of Pathology, of Medicine (Pulmonary, Allergy and Critical Care Medicine) and, by courtesy, of Genetics
BioI am a clinical pathologist and assistant professor in the Departments of Medicine, Pathology, and Genetics (by courtesy) at Stanford. I completed my MD-PhD training at Yale University and my residency training and a post-doctoral fellowship in the Department of Genetics at Stanford University. My experiences as a clinical pathologist and genome scientist have made me passionate about applying cutting-edge technologies to primary patient specimens in order to characterize disease pathologies at the molecular level. The core focus of my lab is to study the mechanisms by which genetic variants influence the risk of disease through effects on intermediate molecular phenotypes.
-
Christina Kong
Professor of Pathology
Current Research and Scholarly InterestsImproving the accuracy of cytologic diagnosis through the use of ancillary techniques on specimens obtained by fine needle aspiration biopsy.
Identifying potential indicators of prognosis in head and neck squamous cell carcinomas.
Evaluating the utility of immunohistochemical stains in refining the diagnosis of squamous dysplasia of the cervix, vulva, and head and neck. -
Christian Kunder
Clinical Associate Professor, Pathology
Current Research and Scholarly InterestsMy main interest is in understanding the biology of human neoplasms, using traditional histopathology, molecular genetic techniques, and other modalities. In particular, I am interested in soft tissue and genitourinary neoplasms, especially prostate cancer.
I am also interested in the classification and nomenclature of neoplasms and in practical research that helps us refine these, using a variety of techniques but still principally guided by histopathology.
I also work on developing next generation sequencing-based tests for genotyping tumors and in expanding the scope of this testing with the goal of identifying patients eligible for novel targeting therapies.
